• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Ferring Pharmaceutical's Director of Medical Science Services Receives Family Building Award From The American Fertility Association (AFA)

Posted on: Tuesday, 7 November 2006, 09:01 CST

NEW YORK, Nov. 7 /PRNewswire/ -- Paul Weathersbee, Ph.D., director of Ferring Pharmaceutical's Medical Science Services, received a "Family Building Award" last night at the American Fertility Association's (AFA) annual benefit, The Kokopelli Ball, at Pier 60 at Chelsea Piers in New York City. The AFA Family Building Award honorees are recognized for their commitment and determination to help those with reproductive difficulties. They are honored for using their expertise and dedication to patient care to help couples build families.

In 2003, Dr. Weathersbee joined Ferring Pharmaceuticals to provide scientific support for Ferring's family of fertility treatments such as BRAVELLE(R) (urofollitropin for injection, purified), MENOPUR(R) (menotropins for injection, USP), REPRONEX(R) (menotropins for injection, USP) and NOVAREL(R) (chorionic gonadotropin for injection, USP). Dr. Weathersbee also oversees a group of regionally based Medical Science Liaisons (MSL's) who provide clinical support to physicians about Ferring's fertility treatments.

"The American Fertility Association is honored to present our 2006 Family Building Award to Dr. Weathersbee for his ongoing commitment to the reproductive community," said Pamela Madsen, executive director of the AFA. "Dr. Weathersbee's outstanding contributions in developing the first media products specifically designed for the in vitro fertilization (IVF) laboratory as well as his continuing efforts have helped educate professionals about advances in the fertility field."

"I am honored to receive the AFA's Family Building Award and to be recognized as a contributor to those who are going through the journey to parenthood," said Dr. Weathersbee. "Ferring shares AFA's commitment and desire to be patient-focused by providing educational resources and ongoing support for those couples trying to build a family."

About Paul Weathersbee, Ph.D.

Paul Weathersbee, Ph.D. received his doctoral degree from the University of Illinois in 1978. He then completed a National Institutes of Health- sponsored post-doctoral position at the University of Washington with the Alcoholism and Drug Abuse Institute. His research led to the development of some of the first data on fetal alcohol syndrome (FAS) in a non-human primate model. In his first academic position at the University of California (UC) Irvine in the Department of Obstetrics and Gynecology, he served as the Reproductive and Endocrine Laboratory director. At UC Irvine, he also implemented trans-abdominal ovarian monitoring into the Division of Reproductive Endocrinology's practice and was the chief sonographer. Dr. Weathersbee then joined Irvine Scientific where he was instrumental in developing the first commercially available culture media designed specifically for IVF. These products included Human Tubal Fluid (HTF) and Synthetic Serum Substitute (SSS).

In May 2003, Dr. Weathersbee brought his considerable expertise in the field to Ferring Pharmaceuticals as director of medical affairs after serving as the associate director of medical affairs at Organon and director of medical affairs at Serono. At Ferring, he oversees the field medical support of the sales team through a group of regionally based Medical Science Liaisons.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets BRAVELLE(R), MENOPUR(R), REPRONEX(R) and NOVAREL(R) in the U.S. to infertility specialists and their patients. Ferring also offers the Q*CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.

Ferring's line of orthopaedic and urology products includes EUFLEXXA(TM), hyaluronic acid for pain from osteoarthritis in the knee. Other products include ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome and DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit http://www.ferringusa.com/ or http://www.ferringfertility.com/.

About the American Fertility Association (AFA)

The American Fertility Association is a national organization headquartered in New York City that provides education, support and advocacy for women and men facing decisions related to family building, reproductive health, preventive health and menopause. The mission of the AFA is to serve as a lifetime resource that helps people make informed choices about their reproductive health through advocacy, education, awareness building and research funding. For more information, call 1-888-917-3777.

Ferring Pharmaceuticals

CONTACT: Andrea Preston of Kovak-Likly Communications for FerringPharmaceuticals, +1-203-762-8833, apreston@klcpr.com

Web site: http://www.ferringfertility.com/http://www.ferringusa.com/

Source: PRNewswire

More News in this Category